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Abstract
Availability of large amounts of in vitro generated b-cells may support replacement therapy in diabetes. However, methods
to obtain b-cells from stem/progenitor cells are limited by inefficient endocrine differentiation. We have recently shown that
the ghrelin gene product obestatin displays beneficial effects on pancreatic b-cell survival and function. Obestatin prevents
b-cell apoptosis, preserves b-cell mass and stimulates insulin secretion in vitro and in vivo, in both normal and diabetic
conditions. In the present study, we investigated whether obestatin may promote in vitro b-cell generation from mouse
pancreatic islet-derived precursor cells. Treatment of cultured islets of Langerhans with obestatin (i) enriched cells
expressing the mesenchymal/neuronal marker nestin, which is associated with pancreatic precursors; (ii) increased cell
survival and reduced apoptosis during precursor selection; (iii) promoted the generation of islet-like cell clusters (ICCs) with
increased insulin gene expression and C-peptide secretion. Furthermore, obestatin modulated the expression of fibroblast
growth factor receptors (FGFRs), Notch receptors and neurogenin 3 (Ngn3) during islet-derived precursor cell selection and
endocrine differentiation. These results indicate that obestatin improves the generation of functional b-cells/ICCs in vitro,
suggesting implications for cell-based replacement therapy in diabetes. Moreover, obestatin may play a role in regulating
pathways involved in pancreas development and regeneration.
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Introduction
In vitro generation of functional b-cells may help to overcome the
shortage of pancreatic islets for replacement therapy in diabetes
[1]. To date, insulin-expressing cells have been derived from stem
cells (SCs), induced pluripotent stem cells (iPSCs) and precursors
obtained from different tissues [1–5]. Functional b-cells in vitro
may be obtained by regulating the expression of genes involved in
pancreatic development. This has been attempted through genetic
reprogramming and/or growth factor supplementation [1–6].
However, despite some success, the use of SCs and genetically
reprogrammed cells has raised both ethical and safety issues,
whereas growth factor supplementation alone resulted in the
generation of b-cells with inefficient insulin synthesis and secretion
[1].
In vivo b-cell regeneration in adult human and mouse pancreas
involving in situ precursor cells [7–10] suggested that their higher
degree of commitment and location would require less manipu-
lation to differentiate into b-cells in in vitro settings [1]. Indeed,
nestin+/vimentin+ mesenchymal-like cells (MLCs) have been
isolated and enriched from both rodent and human islets [11–
15]. These are multipotent stromal cells displaying epigenetic
marks on the insulin gene, indicating priming for b-cells [11,13–
16]. Once expanded, supplementation with specific growth factors
or changes in cell culture condition may induce MLC differen-
tiation into hormone expressing islet-like cell clusters (ICCs)
containing putative b-cells [11,13–15,17]. However, ICCs ineffi-
ciently release insulin/C-peptide in response to glucose and
display poor insulin gene expression [11,12,14,15]. This limitation
is only in part overcome with ICC implantation in mice models of
diabetes [12]. Thus, although in vitro generation of transplantable
ICCs from MLCs appears a promising approach to cell
replacement therapy, it is still technically challenging.
Obestatin, was discovered as a new ghrelin gene-derived
peptide and proposed to bind to the GPR39 orphan receptor
and to exert effects opposed to those of acylated ghrelin on food
intake [18]. However, both assumptions have been questioned and
obestatin physiological role is still quite unknown [19,20]. Our
recent findings suggested that the glucagon-like peptide 1 receptor
(GLP-1R) may be involved in at least part of obestatin activities,
implying therapeutic potential in metabolic dysfunctions and
diabetes [21]. Indeed, obestatin stimulates glucose-induced insulin
secretion in vitro in b-cell lines and human pancreatic islets [21],
and in vivo in mice [22] and in perfused rat pancreas [23].
Moreover, like ghrelin [24], obestatin inhibits apoptosis of
pancreatic b-cells and human islets, and up-regulates genes
essential for b-cell survival and endocrine differentiation [21]. In
vivo obestatin prevents diabetes in streptozotocin (STZ)-treated rats
[25] and reduces insulin resistance in mice fed a high fat diet [22].
Although being mainly produced by the stomach [18], obestatin
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expression in fetal, neonatal and adult pancreas may imply a role
in pancreas development and homeostasis [20,26]. Based on the
foregoing, we hypothesized that obestatin would influence
pancreatic precursor differentiation into b-cells. Therefore, we
studied obestatin effects on in vitro differentiation of mouse
pancreatic islet-derived MLCs into functional b-cells/ICCs.
Materials and Methods
Mouse amidated obestatin (1–23) was from Phoenix Pharma-
ceuticals (Karlsruhe, Germany). Tetramethyl-6-carboxyrhoda-
mine (TAMRA)-obestatin was from Inbios, Naples, Italy. Cell
culture reagents were from GIBCO (Life Technologies, Milan,
Italy). Rabbit cytokeratin 19, GLP-1R, ghrelin and somatostatin
antibodies were from Santa Cruz Biotechnology (DBA, Milan,
Italy). Rabbit GPR39, Oct3/4, PDX1, b-actin antibodies and
guinea pig serum insulin antibodies were from Abcam (Cam-
bridge, UK). Alexa Fluor-labeled antibodies were from Molecular
Probes (Invitrogen, Milan, Italy). Mouse fibroblast growth factor
(FGF2) monoclonal antibody and FGF2-neutralizing antibodies
were from Millipore (Milan, Italy). Ngn3 antibody was from
Chemicon (Milan, Italy). Primers for RT-PCR were synthesized
by Tema Ricerche (Bologna, Italy), All other reagents were from
Sigma Aldrich unless specified in the text.
Animals
Male C57BL6/J mice (6–7 months-old) were used for pancre-
atic islet isolation. Mouse procedures conformed to Guide for Care
and Use of Laboratory Animals of the U.S. National Institute of
Health and all procedures were approved by the animal care and
use committee of the University of Turin. All mice were double-
housed on a 12-h light, 12-h dark cycle (6 am lights on-6 pm lights
off) at 22uC and provided standard chow and water ad libitum.
Mice were anesthetized with tribromoethylalcohol (Avertin;
375 mg/kg i.p.) and euthanized by cervical dislocation.
Islet Isolation and Cell Cultures
Pancreases were excised, minced (stage 1) and digested as
described [27]. Digestion was quenched by addition of FBS, tissues
collected through centrifugation (stage 2), resuspended in RPMI-
1640 with 10% FBS and 2 mM glutamine, and plated in 100 mm
dishes. Within 3–4 days the exocrine and ductal tissues attached to
the dish or died (stage 3). At day 4, 85–95% of floating cell
aggregates were positive to dithizone and 99% negative to the
ductal marker cytokeratin 19 (Cyto19). Islet yield, over six
extractions, was 1142.56190 islets/mouse. Enriched islets were
collected, plated in 6 or 24 multi-well plates coated with 4 mg/ml
fibronectin, 1 mg/ml concanavalin A, 0.001% poly-L-ornithin
(day 1, stage 4) and maintained in DMEM low glucose (5.5 mmol/
L) containing 2 mmol/L glutamine and 10% FBS. <45–55 islets
were plated in each well of a 6-well plate and 20 in a 24-well plate.
Half of the dishes were treated with obestatin (100 nmol/L) every
two days. The majority of islets attached to the dish within 3–6
days (stage 4) and no difference in the number of adherent islets
was observed upon obestatin treatment. During stage 4 mesen-
chymal-like cells (MLCs) emerging from the islets were allowed to
expand. After 4 days fresh medium was added and at day 6
changed into serum free DMEM/F12 containing 26 mmol/L
glucose, 2 mmol/L glutamine, 1400 U/ml LIF, 20 ng/ml FGF2,
20 nmol/L ITS (insulin, selenite, transferrin), 5 mg/ml fibronectin
(day 1, stage 5). Cells were never subcultured and medium was
replaced twice, with obestatin addition (100 nmol/L). From day 6,
with appearance of MLCs tridimensional clusters, fresh medium
(300 ml) was added every two days, with obestatin (100 nmol/L),
up to day 15 of stage 5. All experiments were performed the day
after obestatin treatment.
Islet Counting and Morphometric Analysis
Islets were stained with dithizone for 20 min at 37uC. Red cell
clusters were counted as islets in 10 random fields. Microphoto-
graphs were taken at fixed time intervals (10X). Islet area was
evaluated using Image J software (http://rsbweb.nih.gov/ij/)
using a Leica DM200 microscope and a Leica DFC340 FX
camera. Observations were repeated in 6 different isolations.
Dithizone stained islets were not used for subsequent experiments.
Insulin and C-peptide Secretion
5 islets or ICCs were hand-picked under the microscope and
incubated with different concentrations of D-glucose in Krebs-
Ringer buffer to induce insulin/C-peptide secretion [21]. L-
glucose, was used as molar control. Islets were collected,
supernatants stored at 220uC and tested for insulin and C-
peptide (mouse RIA and ELISA kit, respectively, Alpco Diagnos-
tics, DiaSorin, Saluggia, Italy). Insulin was also tested in medium
alone (300 ml).
Cell Migration
Cell migration was assayed in Boyden’s chambers. Cells were
FGF2-starved for 12 h, detached in PBS/0.5% EDTA and
resuspended in FGF2-deprived serum-free medium. 125,000 cells
were seeded on 0.1% gelatine coated filters (8-mm pore size,
NeuroProbe, DBA, Milan, Italy) and incubated at 37uC for 4 h.
The lower compartment contained serum-free medium either
FGF2-deprived, with 100 ng/ml FGF2 or 100 ng/ml FGF2 and
2.5 mg/ml FGF2-neutralizing antibody. Trapped-cells in the filter
were fixed in cold methanol and stained with 2% Giemsa, then
counted in four different fields under a light microscope (Leika
DMIL).
RT-PCR and Real-time PCR
RNA extraction and reverse transcription were performed as
described [21]. For RT-PCR experiments, cDNA (9 ml) was
amplified (GeneAmp PCR System; Perkin Elmer, Milan, Italy) in
50 ml (94uC for 30 s, for 64uC for 30 s; 72uC for 30 s, 72uC for
7 min.) For semiquantitative analysis, we optimized cDNA
amount and determined the optimal cycle number in the linear
range of PCR amplification for each gene. PCR products were
separated by 2% agarose gel electrophoresis and visualized by
ethidium bromide staining. For real-time PCR, cDNA was treated
with DNA-free DNase (LifeTech, Monza, Italy). Real-time PCR
was performed with 50 ng cDNA, 150 nmol/L of each primer
and the IQ-SYBR-green mastermix (BioRad, Milan, Italy) using
the ABI-Prism 7300 (Applied Biosystems). The expected fragment
sizes, conditions and primers are reported in Table S1.
Apoptosis
Morphological changes in the nuclei of apoptotic cells were
detected by Hoechst 33258, as described [21].
Cell Survival and Dimension
Cell survival was assessed as described [22]. Cells were detached
from dishes with 0.05% trypsin/EDTA and stained with Trypan
blue dye (0.04% w/v; Invitrogen). Cells were counted with a
Countess automated cell counter (Invitrogen). Cell dimension was
automatically calculated during this procedure and expressed in
mm.
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Immunofluorescence Analysis
For differentiation markers, islets/cells were grown on cover-
slips, fixed in ice-cold 4% paraformaldehyde (PFA) and processed
as described [22]. Antibodies used: rabbit polycolonal antibody for
nestin (1:100), Oct3/4 (1:80), Ngn3 (1:100), PDX1 (1:800),
glucagon (1:100), somatostatin (1:100), ghrelin (1:100), rhoda-
mine-labeled anti-ghrelin and anti-somatostatin (both 1:100);
guinea pig serum anti-insulin (1:80); Alexa-488-conjugated anti-
bodies (1:450). For cell proliferation, BrdU (10 mM) was added to
cells at day 3 of stage 4 and at day 6 of stage 5. After 72 h cells
were fixed, treated with 2 mol/L HCl for 45 min at room
temperature, neutralized with 0.1 mol/L sodium borate (pH 8.5)
for 15 min and processed for staining. Alexa-546 labeled anti-
BrdU antibodies (1:50) were used to assess BrdU incorporation.
BrdU positive cells and nuclei were counted (100 to 500 cells) in 20
microscopic fields (X20). TAMRA-obestatin (TAMRA-Obe), was
used to visualize obestatin binding in adherent islets and MLCs on
coverslips as described [22]. For GPR39 and GLP-1R, cells were
permeabilized with 0.2% Triton X-100 after fixation, blocked in
10% goat serum, stained overnight with rabbit polyclonal anti-
GPR39 (1:150) or anti-GLP-1R (1:100) and incubated 1 h at room
temperature with Alexa-488-conjugated goat anti-rabbit antibody
(1:450). Nuclei were stained with DAPI. The same procedure was
followed for TAMRA-obestatin co-localization with nestin. Images
were taken using a Leica DM200 fluorescent microscope and a
Leica DFC340 FX camera. For FGF2, cultures were FGF2-
starved for 2 h or not, fixed in ice-cold4%PFA, then treated as
described [22]. Anti-FGF2 was used at 1:100 for 2 h at room
temperature. 100 to 500 nuclei were counted in 10 microscopic
fields.
Western Blotting
Immunoblot analysis were performed as described [22]. Anti-
nestin antibody was used at 1:500. Blots were reprobed with b-
actin (1:2000) for normalization. Immunoreactive proteins were
visualized with Chemidoc XRS (Bio-Rad, Milan, Italy), and
Figure 1. Overview of culture evolution. For details also see Materials and Methods. (A) Schematic representation of the protocol used to obtain
ICCs from mouse pancreas. Stage 1, pancreas removal; stage 2, pancreas digestion and plating; stage 3, islet enrichment; stage 4, islet adhesion and
MLC appearance; stage 5, MLC migration, clustering and ICC formation. (B) Representative photomicrographs comparing the evolution of control and
obestatin-treated (Obe) cultures. Islet adhesion to the plate induced generation of MLCs (stage 4). During stage 5 MLCs migrate and assemble to
form ICCs. Magnification, 10X. (C) Mean surface area and number of adherent islets (stage 4 day 6) and floating ICCs (stage 5) in either control or
obestatin treated conditions. Results are the mean 6 SEM. *P,0.05, **P,0.01 vs. control; ##P,0.01 vs. same condition at stage 4, day 6. N= 6.
doi:10.1371/journal.pone.0064374.g001
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densitometric analysis performed with Quantity One software
(Bio-Rad).
Glucose Levels and Protein Content
Glucose was measured in cell conditioned medium (300 ml).
Samples were frozen at 280 C and quantified with the GLUC-
PAP kit (Menarini, Florence, Italy), according to manufacturer’s
instructions. Protein concentrations were determined with BCA
Protein Assay Kit (Thermo Scientific, Pierce, Milan, Italy).
Statistical Analysis
Data are presented as means 6 SEM. Results were analyzed
using 2-tailed Student’s t test or two-way ANOVA followed by
Tukey’s HSD for post-ANOVA comparisons (GraphPad Prism
5.0 software, San Diego, CA). Significance was established when
P,0.05.
Results
Obestatin Influences ICC Number and Size
Pancreatic islets were isolated and enriched (stage 1–3), then
cultured for 6 days in serum-containing medium (stage 4), in either
absence or presence of obestatin (Fig. 1A and B). Most of dithizone+
islets attached to the plate, flattened and generated rapidly
proliferating MLCs (Fig. 1A and B). At day 6 (stage 4) obestatin-
treated adherent islets displayed increased area with respect to
control islets (Fig. 1C). At this stage, both untreated and obestatin-
treated islets showed expression of GPR39 and GLP-1R, as
assessed by RT-PCR and immunofluorescent staining (Fig. S1).
The change to serum-free medium (stage 5) caused MLC
migration away from the original islet. By day 6 (stage 5) they
initiated aggregation into tridimensional structures (Fig. 1A and B)
and at day 9 both adherent MLCs and early floating ICCs were
observed (Fig. 1B). Most of MLCs assembled into ICCs by day 15
(Fig. 1A and B). At day 9 (stage 5), obestatin treatment reduced
ICC area, whereas increased ICC number, with respect to control
(Fig. 1C). At day 15 ICC area was comparable between control
and obestatin-treated, although obestatin still increased ICC
number (Fig. 1C). Compared to adherent islets (stage 4, day 6)
ICC size was strongly reduced, whereas ICC number increased, in
both obestatin-treated or control (Fig. 1C).
Obestatin Increases Insulin and Glucagon Expression in
ICCs
Obestatin effects were investigated on insulin and glucagon
mRNA expression in ICCs, at day 9 and 15 (stage 5). ICCs
displayed lower insulin (INS1, INS2) and glucagon at either day 9
or 15 as compared to enriched islets. Notably, obestatin up-
regulated INS1, INS2 and glucagon mRNA at day 9 with respect
to control, but not at day 15 (Fig. 2A–C). Enriched islets, ICCs at
day 9, but also at day 15, were positive to insulin and glucagon also
at protein level (Fig. 3A and B). Obestatin-treated ICCs displayed
enhanced insulin staining at day 9 and 15 and greater glucagon
expression at day 9 compared to control. At day 15, instead,
glucagon was barely detectable in both conditions (Fig. 3B).
Enriched islets were positive for somatostatin (SST) at protein level
(Fig. 3A). Conversely, no gene and protein expression for SST in
ICCs, and for ghrelin in enriched islets and ICCs, was detected.
Enriched islets also expressed PDX1, a b-cell progenitor marker
[3,6,11] (Fig. 3A). Few cells in the islets expressed neurogenin 3
(Ngn3), marker of endocrine-committed pancreatic progenitors
[28], but none expressed the stem cell marker octamer-binding
transcription factor 4 (Oct4) [3] (Fig. 3A). Furthermore, islets were
negative for the pancreatic duct marker cytokeratin 19 (Cyto19)
[8], suggesting absence of duct contamination (Fig. 3A).
Obestatin Enhances Glucose-stimulated C-peptide
Secretion in ICCs
Cells grown in insulin-containing medium may take-up and
release exogenous insulin or display insulin immunoreactivity
without real endocrine differentiation [29]. Therefore, glucose-
stimulated insulin secretion was determined (Fig. S2A) and
compared to insulin levels in cell culture medium (Fig. S2B).
Obestatin-treated ICCs displayed the highest response at day 9,
followed by control ICCs (Fig. S2A),whereas control ICCs at day
15 showed the lowest insulin secretion (Fig. S2A). In culture
medium, insulin levels were sustained until day 6, indicating
additional insulin secretion from residual b-cells, but decreased
abruptly at day 9 when ICCs had formed, confirming uptake of
exogenous insulin (Fig. S2B). Nonetheless, the difference in insulin
release between control and obestatin-treated ICCs suggest de novo
insulin synthesis, in line with the mRNA expression data (Fig. 2A
and B).
Figure 2. Obestatin up-regulates insulin and glucagon gene expression. INS1 (A), INS2 (B) and glucagon (C) mRNA expression in enriched
islets and ICCs at day 9 and day 15 (stage 5) in control (c) and obestatin-treated (Obe) cultures evaluated by Real Time PCR. Gene expression was
normalized to b-actin and reported as percent of enriched islets. *P,0.05, **P,0.01 vs. c; #P,0.05, ##P,0.01 vs. enriched islets. N = 4 (ns, not
significant).
doi:10.1371/journal.pone.0064374.g002
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Figure 3. Differentiation markers and hormone expression in islets and ICCs and obestatin effects on C-peptide secretion. (A)
Fluorescence microscopy images showing enriched islets stained for insulin, glucagon and somatostatin and the indicated markers of progenitors
(magnification, X20). Cytokeratin 19 (Cyto19) was used as marker for pancreatic ducts. (B) Immunofluorescent staining for insulin and glucagon in
ICCs formed in either absence (control) or presence of obestatin at the indicated days (magnification, X40). (C) C-peptide secretion, assessed by ELISA,
from ICCs stimulated at either day 9 or day 15 with the indicated concentrations of glucose. Results are the mean 6 SEM of three different
experiments performed in duplicate (*P,0.05, **P,0.01 vs. control ICCs; #P,0.05 ##P,0.01 vs. enriched islets, EI). (D) GLUT-2 mRNA determined by
RT-PCR. b-actin was used as housekeeping gene. Shown is a representative image of three independent experiments. Buffer alone was used as
negative control (–) (c, control, no obestatin). (E) Densitometric analysis of GLUT-2 mRNA normalized to b-actin and reported as percent of enriched
islets (EI) (*P,0.05 vs. control ICCs; ##P,0.01 vs. EI).
doi:10.1371/journal.pone.0064374.g003
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To confirm de novo insulin synthesis, C-peptide secretion [29,30]
was measured in enriched islets and ICCs, either untreated or
treated with obestatin. Basal C-peptide release in enriched islets
was unchanged upon glucose-stimulated conditions, likely because
of the strict extraction procedures (Fig. 3C). At day 9, control and
obestatin-treated ICCs displayed comparable secretion. However,
at day 15, obestatin strongly increased C-peptide release
compared to control at all glucose concentrations (Fig. 3C), except
at 25 mmol/L where glucose was likely cytotoxic (data not shown).
In line with improved endocrine differentiation and/or glucose
sensitivity, the b-cell glucose transporter 2 (GLUT2) mRNA was
increased at day 15 compared to control in obestatin-treated
ICCs, being barely detectable at day 9. Conversely, GLUT2 was
strongly expressed in enriched islets (Fig. 3D and E).
Obestatin Promotes the Increase of Nestin+ Cells in
Enriched Islets
To elucidate the cellular/biological events underlying obestatin-
induced improvement of ICCs endocrine differentiation, we
assessed proliferation of cells expressing the different hormones
and differentiation markers [3,6,11,28] at day 6 of stage 4, before
the progenitor selection phase. These included nestin, Oct4,
PDX1 and Ngn3. Within the islet, nestin+ cells were the prevalent
population upon adhesion, independently of obestatin treatment
(Table 1). Obestatin increased glucagon+ cell number but
decreased their proliferation, likely improving commitment of
cells to the alpha type. Obestatin did not affect Ngn3+ cell
proliferation, although reduced their percentage, suggesting
differentiation into other cell types [28,31–33]. Conversely,
obestatin increased insulin+ cell number and proliferation,
suppressed somatostatin expression and prevented PDX1+ and
Oct4+ cell proliferation (Table 1).
Obestatin promoted late proliferation of few insulin+ cells in
MLCs (Table 2) and mildly increased ghrelin+ cell number. It also
caused disappearance of Ngn3+ cells. Most of all, obestatin
strongly increased nestin+ MLCs, that likely co-expressed other
markers (Table 2) [3,13,34], although decreasing their late
proliferation (Table 2). Despite these effects, obestatin did not
influence total cell proliferation (15.361.8 BrdU+ cells in control
islets vs. 15.260.1% in obestatin-treated islets, 14.262.2% BrdU+
cells in control MLCs vs. 1464.3% in obestatin-treated MLCs)
and cell dimension (control, 14.961.39 mm; obestatin,
16.260.9 mm). These results confirm previously described mito-
genic effects on b-cells [21] and suggest that obestatin enriches
nestin+ MLCs and negatively modulates Ngn3 expression at stage
4.
Obestatin Binds to Adherent Islets, MLCs and Neuronal-
like Nestin+ cells at the End of Stage 4
In line with the increased percentage of nestin+ MLCs (Table 2),
obestatin up-regulated nestin gene expression and protein at the
end of stage 4 (Fig. 4A and B). Therefore, we investigated whether
obestatin may directly bind to MLCs and islets. At day 6 of stage 4,
TAMRA-obestatin (T-Obe) stained adherent islets and also the
soma of nestin+ neuronal-like cells, in both control and obestatin-
treated cultures (Fig. 4C and D). T-Obe binding was observed in
the majority of obestatin-treated nestin+ MLCs, compared to
control MLCs (Fig. 4E).
Obestatin Reduces Apoptosis during ICC Formation at
Stage 5
Serum-free medium switch at the end of serum-stimulated cell
growth was shown to cause apoptosis selection and expansion of
pancreatic progenitors [11,15,35,36]. We monitored cell survival
and apoptosis at day 2 and 6 (stage 5) when most cells were still
adherent. Protein content in control cultures dramatically
decreased at day 2 and 6 of stage 5, returning to values close to
day 0 (i.e. day 6 of stage 4) only from day 9 (Fig. 5A). Conversely,
in obestatin-treated cultures, protein content was unchanged with
respect to day 0, suggesting increased cell viability (Fig. 5A). Cell
survival was reduced at day 2 and even more at day 6 as compared
to day 0 (Fig. 5B) and was increased by obestatin at day 6 (Fig. 5B).
Obestatin inhibited apoptosis at day 2 compared to control
(Fig. 5C). At day 6, apoptosis was halved in control cells,
suggesting that cell selection was complete [11]; however,
obestatin still displayed antiapoptotic actions (Fig. 5C).
Obestatin Reduces FGF2-induced Cell Migration of MLCs
at Stage 5
At stage 5, FGF2 in the medium is initially required for selection
of pancreatic progenitors [11,15,35,36] and later, to initiate their
endocrine differentiation [37]. FGF2 also plays a role in precursor
cell migration and aggregation into ICCs [37]. We investigated
FGF2 effect on cell migration in obestatin-treated MLCs at day 2
and 6, when most cells were still adherent. At day 2, FGF2
Table 1. Enumeration of endocrine hormone-producing cells
and BrdU+ cells within the islet (day 6, stage 4).
Total cells (%) BrdU positive cells (%)
Control Obestatin Control Obestatin
Insulin 3.561.9 18.866.9* 51.561.5 57.462.6*
Glucagon 31.964.5 40.562 36.667 14.165.1*
Ghrelin 3.962.2 1.860.2 79.2612 78.4612.5
Somatostatin 1.360.8 060 76.45613.6 060**
PDX1 48.969.4 48.3613.2 24.960.6 863.6**
Ngn3 26.269.1 10.963.4* 45.1614.6 41.5612.5
Nestin 65.4611 59.267.6 18.267.5 8.468.4
Oct4 7.261.3 5.761.3 58.464.7 2.562.5**
Results are the mean 6 SEM of three independent experiments (*P,0.05;
**P,0.01; n = 3).
doi:10.1371/journal.pone.0064374.t001
Table 2. Enumeration of endocrine hormone-producing cells
and BrdU+ cells (proliferating MLCs; day 6, stage 4).
Total cells (%) BrdU positive cells (%)
Control Obestatin Control Obestatin
Insulin 5.462 5.563 18.9610.6 53.767.5*
Glucagon 12.863.4 11.165 3.462.3 060
Ghrelin 0.2760.27 3.160** 060 060
Somatostatin 0.460.4 2.462.4 060 464
PDX1 1363.7 11.463.6 12.267 9.364
Ngn3 15610.6 060** 48.562.3 060**
Nestin 20.668.8 97.562.5** 52.5614 21.960.7*
Oct4 12.866 2.862.39 21.6614.1 10610
Results are the mean 6 SEM of three independent experiments (*P,0.05;
**P,0.01; n = 3).
doi:10.1371/journal.pone.0064374.t002
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strongly increased cell migration in cells cultured in the absence of
obestatin (control). This effect was inhibited by an FGF2-
neutralizing antibody, suggesting specificity (Fig. 6A). Conversely,
obestatin strongly increased MLC basal migration at day 2, but no
additional effect was displayed by FGF2 and its neutralizing
antibody (Fig. 6A). At day 6, the FGF2 stimulatory effect on
control cell migration was specific and similar to day 2 (Fig. 6B).
Instead, obestatin-treated cultures showed dramatically reduced
basal migration compared to control cells. Moreover, although
FGF2 increased migration, the neutralizing antibody was ineffec-
tive, suggesting non specific FGF2 action (Fig. 6B). The different
results obtained at day 2 and 6 were independent of cell size,
which was similar in control and obestatin-treated cells (day 2,
control: 18.661.3 mm, obestatin: 20.861.7 mm; day 6, control:
19.260.6 mm, obestatin: 17.461 mm).
Obestatin Reduces FGF Receptor Expression and FGF2
Binding at Stage 5
To further understand obestatin effects on FGF2 altered
sensitivity, we evaluated the expression of FGF2 and its receptors
(FGFRs). Both control and obestatin-treated cultures showed
comparable FGF2 gene expression at day 2, 6 and 9 (Fig. 6C), in
agreement with endogenous FGF2 immunoreactivity in FGF2-
starved cells. Conversely, at day 2 obestatin down-regulated
FGFR3 and FGFR4 mRNA compared to control (Fig. 6C). At day
6, FGFR mRNA levels in control and obestatin-treated cultures
were similar, except for FGFR2c that was slightly down-regulated
by obestatin. At day 9, obestatin-treated cultures displayed
reduced FGFR2b, FGFR2c and FGFR4 expression compared to
control (Fig. 6C), in line with endocrine differentiation [37]. No
change over time and treatment was detected for FGFR1 mRNA
Figure 4. Obestatin up-regulates nestin expression at stage 4 and binds to enriched islets and MLCs. (A) Nestin mRNA assessed by RT-
PCR in control (c) and obestatin-treated cells (Obe). Buffer alone was used as negative control (–). Shown is a representative image of three
independent experiments. (B) Nestin protein expression determined by Western blot in lysates cultures that were either untreated or treated with
obestatin (n = 3). (C) TAMRA-Obestatin (T-Obe) (1 mM) binding to adherent islets and emerging MLCs. The image is representative of both untreated
and obestatin-treated cultures, that were tested in at least three independent experiments (magnification, X20). (D-E) T-Obe (1 mM) binding to
nestin+ neuronal-like cells (D) and to Nestin+ MLCs (E) in both control and obestatin-treated cultures (n = 3; magnification, X40). T-Obe is shown in red,
nestin in green and nuclei in blue (DAPI).
doi:10.1371/journal.pone.0064374.g004
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(Fig. 6C). FGFR gene expression decrease may in part be involved
in the different migratory profile of obestatin-treated cells (Fig. 6A
and B). To determine this, we compared control and obestatin-
treated MLC ability to bind to FGF2. FGF2 immunoreactivity was
assessed in cells cultured in normal conditions (FGF2-containing
medium). At day 2, FGF2 positivity was strongly reduced in
obestatin-treated cells compared to control, whereas at day 6 and
at day 9, it was similar between control and obestatin-treated
MLCs (Fig. 6D). Similar results were obtained in FGF-starved
conditions (Fig. S3). The apparent discrepancy between receptor
expression in the whole culture (Fig. 6C) and of FGF2 binding in
obestatin-treated MLCs at day 9 (Fig. 6D), may depend on the
presence of differentiated ICCs in obestatin-treated cultures.
Indeed, at the periphery of obestatin-treated MLC clusters and
in the central ICC-forming region, FGF2 binding was decreased
with respect to control MLCs (Fig. 6D and S3).
Obestatin Down-regulates Notch Receptor Gene and Up-
regulates Ngn3 Gene and Protein Expression at Stage 5
FGFRs stimulation in pancreatic precursor cells maintains
active Notch signaling and inhibits Ngn3 expression and
endocrine differentiation [28,38]. While data on Notch ligands
Jagged 1,2, Delta-like 1, 3 and 4 expression were inconsistent,
expression of Notch receptors varied during stage 5 (Fig. 7A).
Obestatin reduced Notch 1, 2 and 3 expression at day 2, and
Notch 1, 3 and 4 at day 6. Conversely, it increased Notch 1 and 3
at day 9 (Fig. 7A). Ngn3 gene expression increased at day 6 with
respect to day 2 in both control and obestatin-treated cultures,
suggesting MLC commitment toward endocrine differentiation
(Fig. 7A). As Ngn3 decreases at the end of differentiation, we
hypothesized that inclusion of ICCs in gene expression analysis at
day 9 would mask Ngn3 differential expression in control and
obestatin-treated MLCs. Indeed, we found that Ngn3 in obestatin-
treated MLCs at day 9 was increased vs. control (Fig. 7B).
Moreover, immunofluorescence studies showed that, whereas in
control cultures Ngn3 positivity was low and mainly localized
outside the nuclei, in obestatin-treated MLCs Ngn3 was high and
mainly nuclear (Fig. 7C, monolayer). Moreover, Ngn3 expression
in cells acquiring tridimensional shape was greater in obestatin-
treated MLCs compared to control (Fig. 7C, clustered). These
results suggest that obestatin modulates Notch receptors and up-
regulates Ngn3 gene and protein in MLCs during ICC formation.
Table S2 shows the percentage and proliferation rate of MLCs
expressing the different hormones and differentiation markers at
day 9 of stage 5. Residual MLCs on the plate were either sparse or
clustering to form additional ICCs. All hormones and markers
were highly expressed, especially glucagon, but not insulin, in line
with appearance of b-cells following that of a-cells [28,39].
Obestatin also decreased somatostatin+ cell number and prolifer-
ation and inhibited Ngn3+ cell proliferation, suggesting commit-
ment of Ngn3+ cells toward differentiation (Table S2).
Discussion
This study shows obestatin effects on in vitro generation of ICCs
from islet-derived MLCs. Insulin and glucagon gene expression
and glucose-stimulated C-peptide secretion were increased in
obestatin-treated ICCs as compared to control. Improved in vitro
ICC endocrine differentiation may be explained by obestatin-
induced down-regulation of FGFRs, selective modulation of Notch
receptors and timely induction of Ngn3.
Pancreatic b-cells obtained from human and rodent islet-
derived pancreatic progenitors have shown deficient insulin
synthesis and glucose-induced insulin/C-peptide secretion
[1,11,12,14,15,40]. These limits have been recently improved by
supplementation with growth factors involved in pancreas
regeneration and function [3–5,7,9]. Here, obestatin increased
insulin gene expression in ICCs at day 9 to 30–50% of enriched
islets, a remarkable improvement compared to control ICCs and
to previous findings [1,11–15]. Furthermore, glucose dependent
C-peptide secretion and enhanced GLUT-2 expression in
obestatin-treated ICCs suggested efficient MLC differentiation
into b-cells at day 15. Generation of more functional ICCs
involves obestatin binding to adherent islets and nestin+ MLCs,
enrichment of nestin+ MLCs, reduction of apoptosis and increased
MLC survival. Thus, mainly in nestin+ MLCs, obestatin might
stimulate endocrine differentiation.
Besides obestatin, another major difference from previous
protocols [11,14,15] is that here the cells were never detached
from the original plate, to avoid cell death and quiescence. The
Figure 5. Obestatin promotes cell survival and decreases serum starvation-induced apoptosis at stage 5. (A) Protein content in control
and obestatin-treated cultures at the indicated days. (B-C) Cell survival (B) and apoptosis (C) assessed by Trypan blue exclusion and Hoechst 33258
staining, respectively, at the indicated days. For all graphs, results are the mean 6 SEM of three independent experiments (*P,0.05, **P,0.01 vs.
control; #P,0.05, ##P,0.01, ###P,0.001 vs. day 0).
doi:10.1371/journal.pone.0064374.g005
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Figure 6. Obestatin inhibits cell migration and FGF2 binding to MLCs at stage 5. (A–B) Basal and FGF2-induced cell migration assessed at
day 2 (A) and 6 (B) in either untreated cells (Control) or obestatin-treated cultures (–, no FGF2). Neutralizing antibody against FGF2 (Ab) was used to
verify the specificity of FGF2 effect. The cells were deprived of FGF2 for 12 h then exposed for 4 h to 100 ng/ml of FGF2 and 100 ng/ml of
neutralizing antibody. Results are the mean 6 SEM of three independent experiments performed in duplicate (**P,0.01, ***P,0.001 vs. control;
#P,0.05 vs. –; 1P,0.05, 11P,0.01; ns, not significant). (C) Expression of FGF2 and FGFRs assessed by RT-PCR at the indicated days in control (c) and
obestatin-treated cultures (Obe). Results are representative of three independent experiments. (D) FGF2+ MLCs that were cultured in non FGF2-
starved conditions, in either absence or presence of obestatin at the indicated days. Results shown in the graph (left) are expressed as percent of total
cell number and are the mean 6 SEM of three independent experiments performed in duplicate (**P,0.01 vs. control, #P,0.01 vs. obestatin at day
2). Right panel, representative images (X20) of FGF2 staining (green) (n = 3); nuclei are shown in blue (DAPI).
doi:10.1371/journal.pone.0064374.g006
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older age of mice (six/seven months) may explain this reduced cell
viability and b-cell proliferation [41]. Moreover, the reservoir of
non differentiated cells is likely restricted to those eventually
implicated in pancreatic regeneration [7,8,10,42] and b-cell
survival [10]. Here, our cell separation-free protocol, where
MLCs were maintained with their ‘mother’ islets, may have better
Figure 7. Obestatin modulates Notch receptors and Ngn3 gene expression. (A) RT-PCR analysis showing Notch receptors and Ngn3 mRNA
at the indicated times in control (c) and obestatin-treated (Obe) cultures. Results are representative of three independent experiments. (B) Ngn3
mRNA assessed by real-time PCR at day 9 of stage 5 in adherent MLCs. Results are the mean 6 SEM of three independent experiments performed in
duplicate (*P,0.05 vs. control). (C) Immunofluorescent staining for Ngn3 in adherent cells (monolayer) (X20) and clustered cells (X40), in both control
and obestatin-treated cultures. Ngn3 is shown in green and nuclei in blue (DAPI). Each image is representative of three independent experiments. (D)
Schematic illustration of obestatin mechanisms of action. During pancreatic development FGF2 promotes pancreatic precursor cell proliferation
through FGFRs, inducing Notch signaling and preventing Ngn3 expression. Upon serum removal, FGF2 promotes MLC proliferation and Notch
receptors expression. Obestatin treatment inhibits FGF2 action by reducing expression of FGFRs. Obestatin also inhibits the expression of selective
Notch receptors, leading to increased Ngn3 expression and endocrine differentiation.
doi:10.1371/journal.pone.0064374.g007
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mimicked the in vivo condition, being less harmful to residual
precursors [7,8,10,43]. This culture method may not provide a
renewable supply of ICCs; however, previous studies demonstrat-
ed that ICCs may be replated to generate novel MLCs and ICCs
[13]. Additional studies will clarify whether obestatin-treated ICCs
display increased survival and growth, and achieve the functional
complexity of an islet once transplanted in vivo (4, 5). Our findings
may help improving the current protocols for in vitro b-cell
regeneration and suggest that endogenous/exogenous obestatin
influences pancreas regeneration and development. Interestingly,
enriched islets expressed here PDX1 and Ngn3, both involved in
pancreas regeneration [7,42].
In vivo, blockade of FGF-FGFRs signaling causes disruption of
precursor cell proliferation, untimely endocrine differentiation and
impaired pancreas organogenesis [35,38,44,45]. Obestatin selec-
tively reduced FGFR expression. Moreover, obestatin altered cell
response to FGF2, a mitogen for nestin+ mesenchymal stem cells
and pancreatic progenitors [15,35,36] and chemoattractant for
pancreatic progenitors [37], such that FGF2 failed to induce
migration in obestatin-treated cells. This occurred at day 2 when
FGFR3 and FGFR4 were down-regulated, and at day 6, when
FGF2 binding and FGFR expression were similar to untreated
MLCs.
Here, we found that FGF2 migratory effects were blocked by a
specific anti-FGF antibody in control but not in obestatin treated
cells. This may be interpreted as i) an FGF2-independent
migration of obestatin treated cells at day 2, when the expression
of FGFR specific isoforms was reduced, ii) a partial recovery of
FGF2-induced migration in obestatin treated cells at day 6, when
expression and binding of FGFRs returned similar to control cells.
In both cases, the lack of effect of the neutralizing antibody in
obestatin treated cells may be due to the existing difference in the
pool of receptor-associated/modulating proteins with respect to
control, such that formation of an FGF2-antibody complex may
not prevent binding of FGF2 to its receptor.
As inhibition of FGFR2b and FGFR2c, the most FGF2-
sensitive isoforms, has been associated to incorrect pancreas
organogenesis and early endocrine differentiation [37,45,46],
obestatin-induced down-regulation of FGFR2b and FGFR2c at
day 9 may relate to advanced endocrine differentiation. Moreover,
the small obestatin-induced FGFR2c down-regulation at day 6
suggests that endocrine differentiation starts earlier, in line with
decreased MLC basal migration.
FGFR3 blockade in vivo causes increased proliferation of
immature pancreatic epithelium and islet precursors [47].
Conversely, FGFR4 is expressed in embryonic pancreatic
rudiments, characterized by high proliferation of precursors
[35]. FGFR3 down-regulation by obestatin at day 2 may be
linked to increased proliferation/decreased apoptosis of MLCs.
Moreover, obestatin-induced FGFR4 down-regulation may relate
to reduced proliferation (day 2) and improved differentiation (day
2 and 9) of committed cells.
FGFR stimulates Notch signaling, which inhibits Ngn3 expres-
sion, preventing untimely endocrine differentiation of pancreatic
progenitors and allowing their expansion during pancreas
development [38]. In obestatin-treated cultures, Notch 2 and 4
down-regulation at day 2 and 6 may follow reduced FGFRs
signaling at day 2. Obestatin-induced up-regulation of Notch1 at
day 9 may be part of a feedback mechanism in response to Ngn3
up-regulation [32,38] across stage 5, and may be opposed by the
Notch1 functional antagonist Notch3 [38].
Ngn3, transiently expressed in committed precursors, is essential
to their endocrine differentiation [3,28] and involved in islet
formation [48] and b-cell regeneration [33,42]. Obestatin
increased Ngn3 gene expression in MLCs at day 9 and reduced
their proliferation, suggesting commitment toward the endocrine
fate [31].
Interestingly, glucagon+ cells influence islet formation and
fission during the second wave of Ngn3 up-regulation during
pancreas ontogeny [49]. Obestatin induced glucagon expression at
day 9. Simultaneously, ICC number was increased and ICC size
decreased under obestatin treatment. Regardless of the shorter
time, the above events recall those of islet fission, whereby an
increase of glucagon+ cells at the sites of fission was noticed,
followed by a transient reduction in islet size and increase in their
number [49]. Therefore, obestatin-induced formation of equal-
sized, more abundant and more differentiated ICCs compared to
control, through increase in their number, initial size reduction
and subsequent return to control size, is reminiscent of islet fission.
As glucagon+ cell proliferation is also involved in b-cell/
pancreas regeneration [39], the above mechanisms may also
participate to obestatin-induced pancreas regeneration [25,39]
and suggest a possible role in the endocrine pancreas maturation
[50].
In summary, obestatin enhances in vitro generation of functional
ICCs from islet-derived MLCs, and increases glucose-dependent
C-peptide secretion. Whether these findings would be reproduc-
ible in human pancreatic islets, they may suggest implications in
cell replacement therapy and highlight obestatin importance as
therapeutic candidate in diabetes treatment. Moreover, obestatin
modulation of FGFR/Notch/Ngn3 developmental pathways,
combined to evidence of its early expression in the developing
pancreas [50], suggests a role for this peptide in pancreas
regeneration and formation.
Supporting Information
Figure S1 GPR39 and GLP-1R expression in control and
obestatin-treated cultures. (A) GPR39 and GLP-1R gene
expression assessed by RT-PCR in enriched islets and in cultures
at day 6 of stage 4. Results are representative of three independent
experiments. Buffer alone was used as negative control (–). (B)
Immunofluorescent staining of GPR39 and GLP-1R in MLCs in
control and obestatin-treated cultures at the end of stage 4.
Receptors are shown in green and nuclei in blue (DAPI). Each
image is representative of three independent experiments (X40).
(EPS)
Figure S2 Glucose-induced insulin secretion by ICCs,
and insulin levels in cell culture medium. (A) Insulin
secretion assessed by RIA in ICCs stimulated with the indicated
concentrations of glucose. Values are the mean 6 SEM of three
independent experiments (*P,0.05, **P,0.01 vs. control;
##P,0.01 same condition vs. 0 mM glucose). (B) Insulin content
measured in 300 ml of growth medium from control and obestatin-
treated cultures, at the indicated time points. Insulin content was
also assessed in the medium before being added to the cultures
(Medium stage 4 and 5). Results are the mean 6 SEM of three
independent experiments (#P,0.05 vs. day 9; ##P,0.01 vs. day
6, n = 3).
(EPS)
Figure S3 Obestatin inhibits FGF2 binding to MLCs at
stage 5. FGF+MLCs were cultured in FGF-starved
conditions, in either absence or presence of obestatin
at the indicated days. Graph shows the results expressed as
percent of total cell number, that are the mean 6 SEM of three
independent experiments performed in duplicate (*P,0.05 vs.
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control). Right panel. Representative images (X20) of FGF2
staining (green) (n = 3); nuclei are shown in blue (DAPI).
(EPS)
Table S1 Primers sequences, expected length of ampli-
fication products and PCR conditions (bp, base pair;
mT, melting temperature).
(EPS)
Table S2 Enumeration of endocrine hormone-produc-
ing cells and BrdU+ cells (stage 5, day 9).
(EPS)
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